Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Browse By Topic
Economics & Value
Economics & Value
Articles about real-world healthcare utilization and costs on Value-Based Cancer Care.
Filter by Topic
Accountable Care Organization
Community Oncology
Comparative Effectiveness
Comparative Effectiveness Research
Economics of Cancer Care
Health Economics
Oncology Benefit Edition
Payer-Provider
Pricing
Reimbursement
Value-Based Care
NCCN Panel Addresses Value-Based Care in Oncology
By
Wayne Kuznar
Economics & Value
,
Economics of Cancer Care
,
Value-Based Care
April 2015, Vol 6, No 3
Hollywood, FL—Value-based decision-making at the bedside can be fraught with obstacles, with no clear agreement on what constitutes value, and for whom. In addition, the myriad insurance plans preclude uniform treatment strategies, despite clinical pathways and guidelines intended to reduce variation in care. Finally, value is becoming more difficult to achieve in oncology as each benefit becomes more expensive, with the cost of new therapies outpacing inflation.
Read Article
Regorafenib in Metastatic Colorectal Cancer: High Cost with Little Benefit
By
Chase Doyle
Economics & Value
,
Economics of Cancer Care
March 2015, Vol 6, No 2
San Francisco, CA—According to a recent cost-effectiveness analysis, third-line therapy with regorafenib (Stivarga) in patients with previously treated metastatic colorectal cancer (CRC) far exceeded accepted willingness-to-pay thresholds based on incremental cost-effectiveness ratio (ICER) and quality-adjusted life-years (QALYs). Presented at the 2015 Gastrointestinal Cancers Symposium, the results showed that regorafenib provided an additional 0.04 QALYs, at a cost of $39,391.
Read Article
Preventing Relapse in Myeloma Carries Economic Benefits, Reduces Overall Costs
By
Dana Taylor
Economics & Value
,
Economics of Cancer Care
March 2015, Vol 6, No 2
San Francisco, CA—In what is believed to be the first economic analysis of disease progression of patients with myeloma, researchers found that in patients with newly diagnosed myeloma, the monthly costs are reduced by 68% between the first 4 months through 18 months, but they then rise steeply when the disease relapses. The data were presented at the 2014 American Society of Hematology meeting.
Read Article
Value of New Drugs for Hematologic Cancers—Improving Quality, Extending Survival
By
Wayne Kuznar
Economics & Value
,
Economics of Cancer Care
,
Hematologic Cancers
March 2015, Vol 6, No 2
Although often criticized as being overly expensive, innovations in drug development for hematologic malignancies meet standard benchmarks for cost-effectiveness, delivering value for their cost, suggest a team of health economics researchers led by Peter J. Neumann, ScD, Director, the Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston (Saret CJ, et al. Blood. 2015 Feb 5. Epub ahead of print).
Read Article
Medicaid Reimbursement Rate Has Direct Impact on Cancer Screening Rates
By
Rosemary Frei, MSc
Economics & Value
,
Economics of Cancer Care
October 2014, Vol 5 , No 8
Although increasing the reimbursement rate for cancer screening tests does not consistently improve the likelihood of Medicaid beneficiaries being screened for cancer, raising the rate of reimbursement for office visits does consistently increase the likelihood that they will be screened for cancer, including breast or prostate cancer, according to results of a new analysis of Medicaid claims and enrollment data (Halpern MT, et al.
Cancer
. 2014 Aug 25. Epub ahead of print).
Read Article
Experts Debate Cost-Benefit of Robotic Technology in Head and Neck Cancers
By
Rosemary Frei, MSc
Economics & Value
,
Economics of Cancer Care
October 2014, Vol 5 , No 8
New York, NY—Four head and neck surgeons, 3 of whom use robots in their practice, squared off in a friendly debate on the pros and cons of advanced technology use, focusing on the examples of thyroidectomy and advanced oropharyngeal cancer, at the 2014 American Head and Neck Society annual meeting.
Read Article
Reimbursement Reform in Oncology Must Reward for Quality of Care
By
Dana Butler
Economics & Value
,
Economics of Cancer Care
October 2014, Vol 5 , No 8
The current fee-for-service reimbursement model used in oncology has jeopardized value-based cancer care, according to
Jeffery Ward, MD
, a member of the American Society of Clinical Oncology (ASCO) Workgroup on Payment Reform.
Read Article
Cost Burden Follows Patients with Cancer into Survivorship
By
Charles Bankhead
Economics & Value
,
Economics of Cancer Care
,
Survivorship
,
Policies & Guidelines
September 2014, Vol 5, No 7
The high cost of cancer care follows patients well into survivorship, as annual medical costs and losses in productivity exceed those of people without cancer by 50% to 100%, a study for the Centers for Disease Control and Prevention (CDC) showed (Ekwueme DU, et al. MMWR Morb Mortal Wkly Rep. 2014;63:505-510).
Read Article
Cost of Treatment in Metastatic Breast Cancer Increasing Significantly with End-of-Life Hospitalizations
By
Kate O'Rourke
Economics & Value
,
Economics of Cancer Care
September 2014, Vol 5, No 7
Tampa, FL—Patients with HER2-positive metastatic breast cancer consume 2.5 times more financial resources in their last 6 months of life, according to study results presented at the 2014 Academy of Managed Care Pharmacy meeting.
Read Article
Value Propositions - September 2014
Economics & Value
,
Value Propositions
,
Value Peer-spectives
September 2014, Vol 5, No 7
Read Article
Page 9 of 18
4
5
6
7
8
9
10
11
12
13
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma